Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (1,656,918) $ (1,727,144)
Stock-based compensation expense included in -    
General and administrative costs 339,672 656,032
(Increase) decrease in -    
Advances on research and development contract services 3,224 63,905
Prepaid insurance (21,072) (7,973)
Other prepaid expenses and current assets (41,670) (47,500)
Increase (decrease) in -    
Accounts payable and accrued expenses 143,525 (41,421)
Research and development contract liabilities 198,142 77,764
Net cash used in operating activities (1,035,097) (1,026,337)
Cash flows from financing activities:    
Proceeds from sale of common stock in direct equity offering, net of offering costs 3,689,761
Exercise of common stock warrants 17,100
Payment of deferred offering costs (10,906) (10,467)
Net cash provided by (used in) financing activities (10,906) 3,696,394
Cash:    
Net increase (decrease) (1,046,003) 2,670,057
Balance at beginning of period 4,823,745 5,069,266
Balance at end of period 3,777,742 7,739,323
Supplemental disclosures of cash flow information:    
Interest 2,494 2,099
Income taxes